Citalopram for agitation in Alzheimer’s disease (CitAD): design and methods

BACKGROUND: Agitation is one of the most common neuropsychiatric symptoms of Alzheimer’s disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limited. The citalopram for agitation in Alzheimer’s disease...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Drye, Lea T., Ismail, Zahinoor, Porsteinsson, Anton P., Rosenberg, Paul B., Weintraub, Daniel, Marano, Christopher, Pelton, Gregory, Frangakis, Constantine, Rabins, Peter V., Munro, Cynthia A., Meinert, Curtis L., Devanand, D.P., Yesavage, Jerome, Mintzer, Jacobo E., Schneider, Lon S., Pollock, Bruce G., Lyketsos, Constantine G.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3333484/
https://ncbi.nlm.nih.gov/pubmed/22301195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2011.01.007
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars